Home-Administered Flu Shot is Sold Out

As the 2025-2026 influenza season progresses to its later stages, FluMist® —the only nasal spray flu vaccine in the United States—has officially sold out.

The sell-out of FluMist reflects typical end-of-season patterns, as it has a shorter shelf life compared to injectable flu vaccines.

FluMist, a live attenuated influenza vaccine (LAIV), does not require needles and is approved for healthy individuals aged 2 to 49.

According to AstraZeneca's FluMist website, the flu shot is "no longer available to order for the 2025-2026 flu season."

Users are encouraged to sign up for notifications ahead of the next influenza season.

As of February 20, 2026, AstraZeneca has not disclosed exact dose numbers for FluMist, as product-specific distribution and administration data are typically reported after the season ends. In other countries, FluMist® is known as Fluenz® Tetra.

Historically, FluMist has accounted for a smaller market share than injectable alternatives.

A key highlight of this season was the launch of FluMist Home in August 2025, which allowed for self- or caregiver administration.

This direct-to-consumer service enabled eligible individuals to order the vaccine online through a medical screening process, with home delivery in 34 states, covering approximately 80% of the eligible population.

Meanwhile, as the flu season continues to peak in some states, injectable vaccines remain available from healthcare providers and pharmacies across the USA. For the latest updates, visit cdc.gov/flu, flumist.com, or consult your healthcare provider.